Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCZF7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,808
Award facts
- Contract value 100% obligated
- $30,807.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $30,807.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The award, issued on January 14, 2026, with an ultimate completion date of February 5, 2026, was made on a firm fixed-price basis without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499,999,999 contract awarded November 13, 2025, that positions the company as a critical pharmaceutical supplier for Department of Defense healthcare operations.
The PPV-G GEN V represents a component of the broader $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply chains across military healthcare facilities worldwide. DMS Pharmaceutical Group's established track record of consistent performance across multiple therapeutic categories, including specialty surgical products such as EXPAREL, qualifies the company to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system. The company serves as a primary distributor of branded and generic prescription medications, biologics, vaccines, and medical consumables directly to DLA's Medical Supply Chain division, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FCZF7?
SPE2DR26FCZF7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FCZF7 worth?
The government has obligated $30,808 on SPE2DR26FCZF7.
Is contract SPE2DR26FCZF7 an order under another contract?
Yes. SPE2DR26FCZF7 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZF7 competed?
The extent of competition for SPE2DR26FCZF7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award